Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition - Novo Nordisk Set to Close Catalent Deal Without FTC Challenge - Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial - The Score: GM, Macy's, Novo Nordisk and More Stocks That Defined the Week - Novo Nordisk readies trial results for next-generation weight-loss drug - Novo Nordisk shares jump 8% after Wegovy sales beat expectations - Novo Nordisk maintains booming sales of obesity and diabetes drugs - Sales of Novo Nordisk's blockbuster weight loss drug Wegovy continue to soar - Wegovy sales are slaying for Novo Nordisk right now - Novo Nordisk's Wegovy Sales Beat Expectations